Total Payments
$2,165
2024 Payments
$389.68
Companies
22
Transactions
140
Medicare Patients
5,464
Medicare Billing
$474,301
Payment Breakdown by Category
Food & Beverage$2,157 (99.6%)
Education$7.95 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,157 | 138 | 99.6% |
| Education | $7.95 | 2 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $493.29 | 31 | $0 (2021) |
| Novo Nordisk Inc | $352.91 | 19 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $215.44 | 16 | $0 (2024) |
| ABBVIE INC. | $205.04 | 14 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $137.58 | 9 | $0 (2021) |
| Lilly USA, LLC | $132.68 | 9 | $0 (2024) |
| GlaxoSmithKline, LLC. | $115.11 | 7 | $0 (2024) |
| PFIZER INC. | $102.61 | 7 | $0 (2020) |
| Allergan, Inc. | $77.58 | 6 | $0 (2020) |
| Genentech USA, Inc. | $38.88 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $389.68 | 25 | ABBVIE INC. ($132.91) |
| 2023 | $181.33 | 10 | GlaxoSmithKline, LLC. ($45.33) |
| 2022 | $177.01 | 10 | Novo Nordisk Inc ($60.48) |
| 2021 | $182.99 | 10 | Janssen Pharmaceuticals, Inc ($61.59) |
| 2020 | $339.31 | 24 | Janssen Pharmaceuticals, Inc ($198.84) |
| 2019 | $335.99 | 20 | Janssen Pharmaceuticals, Inc ($141.08) |
| 2018 | $170.80 | 12 | Janssen Pharmaceuticals, Inc ($41.34) |
| 2017 | $387.85 | 29 | AstraZeneca Pharmaceuticals LP ($65.42) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: RESPIRATORY | ||||||
| 10/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: RESPIRATORY | ||||||
| 09/24/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: Endocrinology | ||||||
| 09/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.53 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.05 | General |
| 08/27/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: PSYCHIATRY | ||||||
| 08/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.10 | General |
| Category: NEUROSCIENCE | ||||||
| 08/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.46 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.71 | General |
| 07/23/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: RESPIRATORY | ||||||
| 07/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: NEUROSCIENCE | ||||||
| 05/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Cardio-renal | ||||||
| 04/23/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: PSYCHIATRY | ||||||
| 04/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.35 | General |
| Category: NEUROSCIENCE | ||||||
| 04/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Diabetes | ||||||
| 04/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: NEUROSCIENCE | ||||||
| 04/09/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: Diabetes | ||||||
| 03/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: NEUROSCIENCE | ||||||
| 02/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.04 | General |
| Category: NEUROSCIENCE | ||||||
| 02/06/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Diabetes | ||||||
| 01/03/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,358 | 2,381 | $157,216 | $114,615 |
| 2022 | 14 | 1,246 | 2,585 | $163,800 | $121,102 |
| 2021 | 17 | 1,288 | 3,201 | $176,625 | $124,264 |
| 2020 | 21 | 1,572 | 3,283 | $166,947 | $114,320 |
Total Patients
5,464
Total Services
11,450
Medicare Billing
$474,301
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 428 | 428 | $59,920 | $51,030 | 85.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 250 | 452 | $47,056 | $32,004 | 68.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 215 | 405 | $29,238 | $18,246 | 62.4% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 66 | 66 | $4,915 | $4,684 | 95.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 73 | 74 | $2,220 | $2,109 | 95.0% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 111 | 111 | $2,775 | $1,856 | 66.9% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 12 | 12 | $2,280 | $1,822 | 79.9% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 36 | 57 | $2,850 | $1,526 | 53.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 55 | 105 | $2,310 | $1,036 | 44.8% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 39 | 48 | $480.00 | $189.12 | 39.4% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 33 | 189 | $2,304 | $72.84 | 3.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 40 | 434 | $868.00 | $40.05 | 4.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 349 | 862 | $89,714 | $60,413 | 67.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 287 | 287 | $35,020 | $34,488 | 98.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 113 | 146 | $10,550 | $7,902 | 74.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 72 | 72 | $5,040 | $4,928 | 97.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 30 | $4,216 | $3,093 | 73.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 78 | 78 | $2,316 | $2,118 | 91.5% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 13 | 13 | $2,210 | $2,096 | 94.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 69 | 188 | $4,136 | $2,008 | 48.5% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2022 | 34 | 62 | $3,100 | $1,618 | 52.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 12 | 15 | $1,623 | $1,111 | 68.4% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 60 | 60 | $1,475 | $1,019 | 69.1% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2022 | 36 | 42 | $420.00 | $166.40 | 39.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 44 | 252 | $3,024 | $98.20 | 3.2% |
About Dr. Gregory Stidham, MD
Dr. Gregory Stidham, MD is a Family Medicine healthcare provider based in Fayette, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1831183219.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Stidham, MD has received a total of $2,165 in payments from pharmaceutical and medical device companies, with $389.68 received in 2024. These payments were reported across 140 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($2,157).
As a Medicare-enrolled provider, Stidham has provided services to 5,464 Medicare beneficiaries, totaling 11,450 services with total Medicare billing of $474,301. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Fayette, AL
- Active Since 08/31/2005
- Last Updated 02/18/2013
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1831183219
Products in Payments
- XARELTO (Drug) $404.59
- VRAYLAR (Drug) $234.73
- FARXIGA (Drug) $183.68
- JARDIANCE (Drug) $121.82
- TRELEGY ELLIPTA (Drug) $115.11
- Ozempic (Drug) $101.97
- Rybelsus (Drug) $83.68
- ELIQUIS (Drug) $72.82
- MOUNJARO (Drug) $67.75
- RYBELSUS (Drug) $51.72
- INVOKANA (Drug) $50.56
- TRULICITY (Drug) $41.80
- Tresiba (Drug) $40.80
- Victoza (Drug) $40.07
- Xofluza (Drug) $38.88
- INVOKAMET (Drug) $38.14
- REXULTI (Drug) $37.21
- FLUZONE HIGH-DOSE (Biological) $29.63
- Korlym (Drug) $29.45
- STIOLTO (Drug) $27.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Fayette
Andrea Schuster, M.d, M.D
Family Medicine — Payments: $4,846
Family Medicine $4,846
Dr. Charles Nolen, M.d, M.D
Family Medicine — Payments: $4,825
Family Medicine $4,825
Dakota Acton Jones, M.d, M.D
Family Medicine — Payments: $1,225
Family Medicine $1,225
Garry Magouirk, Md, MD
Family Medicine — Payments: $1,030
Family Medicine $1,030
Dr. Janice Hudson, Md, MD
Family Medicine — Payments: $971.64
Family Medicine $971.64
Dr. Frederick Yerby, M.d, M.D
Family Medicine — Payments: $852.99
Family Medicine $852.99